Ultra-sensitive biomarker platform delivers comprehensive evaluation of plasma NfL’s utility across 13 neurodegenerative disorders, Down syndrome and depression BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 7, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 2, 2021-- Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix , Kevin Hrusovsky will be delivering a virtual

Toloue brings deep expertise and industry acumen to lead the Company’s strategic expansion into diagnostics BILLERICA, Mass. --(BUSINESS WIRE)--May 11, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision

Q1 GAAP revenue including grant revenue $27.2M ; Q1 non-GAAP revenue $24.9M , an increase of 58% versus prior year BILLERICA, Mass. --(BUSINESS WIRE)--May 5, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling

BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for first quarter 2021 after the close of trading on Wednesday,

Pharmaceutical veteran adds deep expertise in commercial and corporate strategy BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the

BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 22, 2021-- Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a webinar with leading industry experts to discuss neurological advancements related to the ultra-sensitive

BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 21, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has appointed Shawn Stetson as the Company's interim chief financial officer,

Company’s SARS-CoV-2 N-Protein Assay measures viral antigen in plasma, dried blood spots and saliva in more than 90 percent of COVID-19 PCR+ positive donors, including those without symptoms BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 26, 2021-- Quanterix Corporation (NASDAQ:QTRX), a company

Oral and poster presentations demonstrate the potential of company’s ultra-sensitive protein biomarker technology and assays to validate blood biomarkers as important tools for neurodegenerative disease stratification and clinical trial enrollment and efficacy BILLERICA, Mass.